Sign In
Buy JNJ
$239.08
+7.79 (+3.37%)
At Close: Jun 23, 2026
Q2 Earnings Season Preview and Featured Analyst Reports for J&J, AMD & Union Pacific
04:55pm, Monday, 27'th Jun 2022 Zacks Investment Research
Today's Research Daily features preview of the Q2 earnings season and new research reports for J&J (JNJ), AMD (AMD), and Union Pacific (UNP).
Pfizer booster improved to fight omicron, as hospitalizations rise to 3-month high
04:03pm, Monday, 27'th Jun 2022 MarketWatch
Pfizer Inc. and partner BioNTech SE said the update to their COVID-19 booster shot showed a "high immune response" against the omicron variant, in time for an FDA meeting and as the daily average of C
Emergent's (EBS) Anthrax Vaccine BLA Gets FDA Acceptance
02:31pm, Monday, 27'th Jun 2022 Zacks Investment Research
The FDA accepts Emergent's (EBS) BLA seeking approval for its new anthrax vaccine, AV7909. A decision is expected in April next year.
These 3 Dividend ETFs Are a Retiree's Best Friend
12:12pm, Monday, 27'th Jun 2022 The Motley Fool
When your paychecks stop coming in, you'll need a plan for replacing that income.
Is Franklin U.S. Low Volatility H (LVHD) a Strong ETF Right Now?
10:20am, Monday, 27'th Jun 2022 Zacks Investment Research
Smart Beta ETF report for LVHD
Should iShares Russell Top 200 Value ETF (IWX) Be on Your Investing Radar?
10:20am, Monday, 27'th Jun 2022 Zacks Investment Research
Style Box ETF report for IWX
Still Think Tesla Is Expensive? This Stat Will Change Your Mind
10:01am, Monday, 27'th Jun 2022 The Motley Fool
When you factor in growth, the auto stock is actually very reasonably priced.
2 Dividend Stocks for a Lifetime of Passive Income
09:33am, Monday, 27'th Jun 2022 The Motley Fool
These reliable businesses have delivered steadily growing profits to shareholders for decades, and they could keep it going indefinitely.
Could Johnson & Johnson Stock Help You Retire A Millionaire?
10:55am, Sunday, 26'th Jun 2022 The Motley Fool
Over the past decade, the stock has closely tracked the S&P 500.
The 3-Bucket SWAN Portfolio For The Good Times And Bad
01:00pm, Saturday, 25'th Jun 2022 Seeking Alpha
No investment strategy is perfect. What's a near-perfect portfolio strategy? Click here to find out.
Raymond James Thinks Med Tech Investors are Somewhat 'Paralyzed' Ahead Of Q1 Earnings
07:27pm, Thursday, 14'th Apr 2022 Benzinga
Raymond James has outlined its expectations for next week when Johnson & Johnson (NYSE: JNJ), Abbott Laboratories (NYSE: ABT), and Intuitive Surgical Inc (NASDAQ: ISRG) will report Q1 FY22 earn
Genmab (GMAB), AbbVie's Epcoritamab Successful in LBCL Study
02:01pm, Thursday, 14'th Apr 2022 Zacks Investment Research
Genmab (GMAB) and AbbVie are co-developing epcoritamab as a potential treatment for hematologic malignancies including NHL and LBCL. A phase I/II study evaluating it in LBCL achieves a response rate o
What 6 Analyst Ratings Have To Say About Johnson & Johnson
01:13pm, Thursday, 14'th Apr 2022 Benzinga
Analysts have provided the following ratings for Johnson & Johnson (NYSE:JNJ) within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
0
2
4
0
0
2 Unstoppable Green Flags for AbbVie
11:00am, Thursday, 14'th Apr 2022 The Motley Fool
There's a silver lining around an approaching dark cloud.
Healthcare ETFs Outperform Amid Rising Uncertainties
10:24pm, Wednesday, 13'th Apr 2022 Zacks Investment Research
Investors are seeking refuge in healthcare stocks as inflation and rates rise
